Akari Therapeutics (AKTX)

$3.19 0.65 (25.59%)

19:59 EST AKTX Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 48.67M

PE Ratio -

EPS -

Volume (Avg. Vol.) 1.17M

Day's Range 2.56 - 3.19

52-Week Range 0.87 - 3.19

Dividend & Yield N/A (N/A)

AKTX Stock Predictions, Articles, and Akari Therapeutics News

From InvestorPlace
From the Web

Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today

By William White, InvestorPlace Writer Aug 14, 2019

Some recent biopharma news concerning Akari Therapeutics getting Fast Track approval from the FDA has AKTX stock flying high on Wednesday.

3 Stocks to Watch on Friday: BlackBerry Ltd (BBRY), Akari Therapeutics PLC (ADR) (AKTX) and Voxeljet AG (ADR) (VJET)

By Karl Utermohlen, InvestorPlace Writer Mar 31, 2017

BlackBerry (BBRY) and VoxelJet (VJET) were moving Friday on earnings, while Akari Therapeutics (AKTX) received some positive medical news.

Stocks That Hit 52-Week Highs On Friday

From Benzinga Jan 15, 2021

This morning 150 companies reached new 52-week highs. Interesting Points: Eli Lilly (NYSE:LLY) was the largest firm by market cap to set a new 52-week high. Ikonics (...

12 Health Care Stocks Moving In Monday's After-Market Session

From Benzinga Jan 11, 2021

Gainers Iridex (NASDAQ:IRIX) stock rose 29.02% to $3.69 during Monday's after-market session. This security traded at a volume of 171.4K shares come close, making up 77.9% of...

The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal

From Benzinga Oct 29, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28) Blueprint Medicines Corp (...

Akari's nomacopan to enter late-stage skin blistering disorder study during next year (NASDAQ:AKTX)

From Seeking Alpha Oct 1, 2020

Akari Therapeutics (AKTX -4.6%) completes a scientific advice meeting with the European Medicines Agency (EMA) prior to initiation of a Phase 3 study of nomacopan for the treatment of bullous pemphigoid (BP), a rare skin disorder characterized by large fluid-filled blisters on areas of the skin that often flex (e.g., arm pits, upper thighs).Similar to agreement from the FDA at an End of Phase 2 meeting, the EMA has agreed to Akari’s proposal for a Phase 3 study.The company plans to initiate the study in both the U.S and Europe during 1H of 2021.

Akari Therapeutics +7% on developmental plans of nomacopan for COVID-19 (NASDAQ:AKTX)

From Seeking Alpha Aug 31, 2020

Akari Therapeutics (AKTX +6.5%) intends to develop nomacopan as a potential treatment for COVID-19 pneumonia through integrated clinical trial programs in U.S., U.K.

AMRN, DVAX among premarket gainers

From Seeking Alpha Aug 31, 2020

Aimmune Therapeutics (NASDAQ:AIMT) +171% on being acquired by Nestle.Akcea Therapeutics (NASDAQ:AKCA) +59% as Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics.Genworth Financial (NYSE:GNW) +38%.UTStarcom Holdings (NASDAQ:UTSI) +29% on launching SkyFlux converged packet transport platform.Venator Materials (NYSE:VNTR) +18% on $100M investment from SK Capital Partners.Canaan (NASDAQ:CAN) +16% on Q2 results.GameStop (NYSE:GME) +14% after RC ventures reports 9% stake.FSD Pharma (NASDAQ:HUGE) +10% on filing IND for FSD201 to treat COVID-19 patients.CorMedix (NYSEMKT:CRMD) +11%.Turquoise Hill Resources (NYSE:TRQ) +9% on increased 2021 gold production outlook.Akari Therapeutics (NASDAQ:AKTX) +13%.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

D

Sell